Biotech Values

[ilpapa]

ASTX. I own a token amount and I believe someone here mentioned the company a little while ago.

DUBLIN, Calif., July 30, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (ASTX), today reported financial results for the second quarter ended June 30, 2012. The Company reported net income for the 2012 second quarter of $1.2 million, or $0.01 per basic and diluted share, compared with $903,000, or $0.01 per basic and diluted share, for the same prior year period. The Company reported net income for the six months ended June 30, 2012 of $5.5 million, or $0.06 per basic and $0.05 per diluted share, compared with a net income of $6.4 million, or $0.11 per basic and $0.10 per diluted share, for the same prior year period.

Highlights of 2012 Second Quarter:

Dacogen(R) (decitabine) for Injection received a positive regulatory recommendation in the European Union (EU) for the treatment of elderly Acute Myeloid Leukemia (AML). If approved, Dacogen would receive 10 years of market exclusivity in the EU and the Company would earn a milestone payment of $5.0 million.
Dacogen second quarter royalty revenue increased 25% from the prior year's second quarter, from $11.5 million to $14.4 million.
Earned $5.4 million on Phase I trial initiation of a Fibroblast Growth Factor Receptor (FGFR) kinase inhibitor from the collaborative drug discovery program with Janssen Pharmaceutica NV.
Ended 2012 second quarter with $121 million in cash & marketable securities.
Revised 2012 financial guidance from a forecasted net loss of $15 million to a net loss of $5 million with the potential to be operationally cash flow positive.


Full release here

http://finance.yahoo.com/news/astex-pharmaceuticals-reports-2012-second-200000130.html